Literature DB >> 7781190

Effects of antiepileptic drugs on EEG background activity in children with epilepsy: initial phase of therapy.

T Konishi1, Y Naganuma, K Hongou, M Murakami, M Yamatani, T Okada.   

Abstract

The effects of antiepileptic drugs (AED) on EEG background activity were evaluated in 37 newly treated children with epilepsy, compared with 46 age-matched healthy controls. Before AED therapy, the children with epilepsy, both partial (treated with carbamazepine, CBZ group) and generalized seizures (treated with valproic acid, VPA group), already exhibited significant slowing of EEG with increased delta and decreased alpha power. Following 3 to 6 months of AED therapy, this EEG slowing was enhanced in the CBZ group and reduced in the VPA group. Following 1 year of AED therapy, an increase in frequency was recognized in the CBZ group. These results suggest that 1) most children with epilepsy already exhibit slowing of the EEG at the onset of seizures, which may reflect CNS developmental deficit, 2) the short-term effects on EEG are different between CBZ and VPA, and 3) EEG development with age continues under continuous AED administration. The EEG background activity in children with epilepsy is affected by many factors, which include the underlying CNS dysfunction of the epilepsy itself and also AED therapy (type of AEDs, duration of therapy, etc).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781190     DOI: 10.1177/155005949502600209

Source DB:  PubMed          Journal:  Clin Electroencephalogr        ISSN: 0009-9155


  2 in total

1.  Test-retest reliability of the N2 event-related potential in school-aged children with autism spectrum disorder (ASD).

Authors:  Amanda Cremone-Caira; Akshita Vaidyanathan; Danielle Hyatt; Rachel Gilbert; Tessa Clarkson; Susan Faja
Journal:  Clin Neurophysiol       Date:  2019-11-25       Impact factor: 3.708

Review 2.  Quantitative Pharmaco-Electroencephalography in Antiepileptic Drug Research.

Authors:  Yvonne Höller; Christoph Helmstaedter; Klaus Lehnertz
Journal:  CNS Drugs       Date:  2018-09       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.